CD Biosynsis offers a premier platform for Site-Specific PEGylation, a cutting-edge bioconjugation technology designed to overcome the limitations of traditional random PEGylation. While standard methods often result in heterogeneous mixtures with unpredictable bioactivity, our site-specific approach ensures that polyethylene glycol (PEG) polymers are attached to precisely defined locations on the protein or peptide. This surgical precision maximizes therapeutic efficacy, improves pharmacokinetic profiles, and simplifies regulatory characterization by providing a homogeneous drug product.
Our expert team utilizes advanced chemical and biological strategies to target specific functional handles, such as the N-terminus, engineered cysteine residues, or unique enzymatic recognition motifs. By integrating computational structural modeling with high-resolution analytical verification, we ensure that the PEG shield is positioned to provide optimal protection against proteolysis and immunogenicity without interfering with the molecule’s active site or receptor-binding domains. Whether you are developing long-acting cytokines, stabilized enzymes, or next-generation antibody fragments, our site-specific PEGylation services deliver the molecular consistency required for clinical success.
Get a QuoteRandom PEGylation typically targets the numerous lysine residues on a protein surface, leading to a "cloud" of positional isomers that vary in potency and stability. In contrast, Site-Specific PEGylation focuses on a single, predetermined attachment point. This enables the creation of a well-defined molecular entity with a specific hydrodynamic radius, slowing renal clearance while maintaining a predictable interaction with biological targets. This level of control is essential for modern biopharmaceutical development where batch-to-batch consistency is paramount.
Our platform excels in identifying the "sweet spot" for conjugation. Using 3D structural analysis, we predict how PEG placement affects the protein’s thermal stability and binding kinetics. We offer a diverse array of site-specific chemistries, including pH-controlled reductive alkylation, thiol-selective maleimide coupling, and sophisticated enzymatic ligations. This versatility allows us to modify almost any protein chassis, ensuring that the resulting conjugate exhibits a significantly extended half-life and reduced immunogenicity while retaining its full biological potency.
Mechanism
Utilizing the pKa difference between the alpha-amino group and lysine epsilon-amino groups to achieve selective modification at pH 5.0 to 6.0.
Benefit
Preserves native lysine residues and ensures a single PEG attachment point at the start of the protein chain.
Mechanism
Targeting natural or genetically engineered free thiol groups using maleimide or haloacetyl chemistries.
Benefit
High regioselectivity due to the rarity of surface cysteines, allowing for precise control over the polymer-to-protein ratio.
Mechanism
Utilizing enzymes like transglutaminase or sortase to recognize specific peptide motifs for polymer attachment.
Benefit
Unmatched specificity and mild reaction conditions, ideal for fragile proteins where chemical methods may be too harsh.
Our systematic technical pipeline ensures high-yield conjugation and definitive validation of site-specificity.
1. Structural Assessment
2. Reaction Optimization
3. High-Res Purification
4. Structural Validation
Bioinformatic and structural modeling to identify optimal sites distal to the active pocket. Evaluation of N-terminal accessibility or cysteine availability.
Screening of PEG molecular weights and architectures. Optimization of pH, stoichiometry, and temperature to maximize mono-PEGylation yield.
Verification of site-specificity via LC-MS/MS peptide mapping. Potency testing via bioassays or SPR to confirm biological activity retention.
Homogeneity Guaranteed
Eliminate positional isomers, providing a uniform drug profile for regulatory IND/NDA filings.
Activity Preservation
Precision placement distal to active sites ensures therapeutic potency is maintained after modification.
Versatile Toolbox
Multiple chemical and enzymatic handles allow us to modify nearly any protein, including those without natural free thiols.
Analytical Proofing
Comprehensive characterization data including peptide mapping and intact mass spec for every project.
1. Why is site-specific PEGylation preferred over random PEGylation?
Random PEGylation creates a mixture of molecules with varying activity and stability. Site-specific PEGylation provides a single, uniform product, ensuring consistent clinical performance and easier regulatory approval.
2. How is N-terminal specificity achieved?
We exploit the pKa difference between the N-terminal alpha-amine and lysine epsilon-amines. In slightly acidic buffers (pH 5-6), only the N-terminal group is deprotonated and reactive toward PEG-aldehyde reagents.
3. What if my protein doesn't have a free cysteine residue?
We can introduce a specific cysteine via site-directed mutagenesis (Thio-modification) or utilize enzymatic methods that recognize small peptide tags.
4. Does PEGylation always reduce the activity of the protein?
Site-specific placement distal to the active site minimizes activity loss. While a small drop in affinity may occur, it is usually offset by the significantly increased half-life in vivo.
5. How do you verify the PEG is attached to the correct site?
We utilize high-resolution LC-MS/MS peptide mapping. By identifying the mass-shifted fragment in the protein digest, we definitively prove the conjugation site.
6. Is the PEG attachment stable in blood?
Yes, we use stable thioether, amide, or secondary amine linkages. We also offer cleavable linkers if triggered release of the native protein is required.
7. What is the typical turnaround time?
A standard project from design to purified, characterized conjugate typically takes 8 to 12 weeks, depending on the complexity of the protein.
8. Can you handle large-scale PEGylation projects?
Yes, our purification systems (TFF and process-scale chromatography) are designed to handle both milligram research quantities and gram-scale clinical batches.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.